147 related articles for article (PubMed ID: 29278101)
21. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type.
Martino Adami PV; Orellana A; García P; Kleineidam L; Alarcón-Martín E; Montrreal L; Aguilera N; Espinosa A; Abdelnour C; Rosende-Roca M; Pablo Tartari J; Vargas L; Mauleón A; Esteban-De Antonio E; López-Cuevas R; Dalmasso MC; Campos Martin R; Parveen K; Andrade Fuentes VM; Amin N; Ahmad S; Ikram MA; Lewczuk P; Kornhuber J; Peters O; Frölich L; Rüther E; Wiltfang J; Tarraga L; Boada M; Maier W; de Rojas I; Cano A; Sanabria A; Alegret M; Hernández I; Marquié M; Valero S; van Duijn CM; Wagner M; Jessen F; Schneider A; Sáez Goñi ME; González Pérez A; Ruiz A; Ramírez A
Brain; 2022 Jul; 145(7):2507-2517. PubMed ID: 35088840
[TBL] [Abstract][Full Text] [Related]
23. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
[TBL] [Abstract][Full Text] [Related]
24. Genetic study of multimodal imaging Alzheimer's disease progression score implicates novel loci.
Scelsi MA; Khan RR; Lorenzi M; Christopher L; Greicius MD; Schott JM; Ourselin S; Altmann A
Brain; 2018 Jul; 141(7):2167-2180. PubMed ID: 29860282
[TBL] [Abstract][Full Text] [Related]
25. Nonlinear biomarker interactions in conversion from mild cognitive impairment to Alzheimer's disease.
Popescu SG; Whittington A; Gunn RN; Matthews PM; Glocker B; Sharp DJ; Cole JH;
Hum Brain Mapp; 2020 Oct; 41(15):4406-4418. PubMed ID: 32643852
[TBL] [Abstract][Full Text] [Related]
26. Association of brain amyloid-β with cerebral perfusion and structure in Alzheimer's disease and mild cognitive impairment.
Mattsson N; Tosun D; Insel PS; Simonson A; Jack CR; Beckett LA; Donohue M; Jagust W; Schuff N; Weiner MW;
Brain; 2014 May; 137(Pt 5):1550-61. PubMed ID: 24625697
[TBL] [Abstract][Full Text] [Related]
27. Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease.
Petrella JR; Hao W; Rao A; Doraiswamy PM
Comput Math Methods Med; 2019; 2019():6216530. PubMed ID: 30863455
[TBL] [Abstract][Full Text] [Related]
28. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
29. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
[TBL] [Abstract][Full Text] [Related]
30. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
[TBL] [Abstract][Full Text] [Related]
31. The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer's disease.
Walsh P; Sudre CH; Fiford CM; Ryan NS; Lashley T; Frost C; Barnes J;
Neurobiol Aging; 2021 Jan; 97():10-17. PubMed ID: 33070094
[TBL] [Abstract][Full Text] [Related]
32. Joint space-time Bayesian disease mapping via quantification of disease risk association.
Baer DR; Lawson AB; Joseph JE
Stat Methods Med Res; 2021 Jan; 30(1):35-61. PubMed ID: 33595403
[TBL] [Abstract][Full Text] [Related]
33. Multi-state Markov model in outcome of mild cognitive impairments among community elderly residents in Mainland China.
Yu HM; Yang SS; Gao JW; Zhou LY; Liang RF; Qu CY
Int Psychogeriatr; 2013 May; 25(5):797-804. PubMed ID: 23286508
[TBL] [Abstract][Full Text] [Related]
34. Apolipoprotein E ε4 and ε3 alleles associate with cerebrospinal fluid tau and cognition in the presence of amyloid-β in mild cognitive impairment but not in Alzheimer's disease.
Xing F; Meng T; Therriault J; Luo J; Zhang H;
J Integr Neurosci; 2021 Jun; 20(2):277-286. PubMed ID: 34258926
[TBL] [Abstract][Full Text] [Related]
35. Two Routes to Alzheimer's Disease Based on Differential Structural Changes in Key Brain Regions.
Hollenbenders Y; Pobiruchin M; Reichenbach A;
J Alzheimers Dis; 2023; 92(4):1399-1412. PubMed ID: 36911937
[TBL] [Abstract][Full Text] [Related]
36. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.
van Maurik IS; Vos SJ; Bos I; Bouwman FH; Teunissen CE; Scheltens P; Barkhof F; Frolich L; Kornhuber J; Wiltfang J; Maier W; Peters O; Rüther E; Nobili F; Frisoni GB; Spiru L; Freund-Levi Y; Wallin AK; Hampel H; Soininen H; Tsolaki M; Verhey F; Kłoszewska I; Mecocci P; Vellas B; Lovestone S; Galluzzi S; Herukka SK; Santana I; Baldeiras I; de Mendonça A; Silva D; Chetelat G; Egret S; Palmqvist S; Hansson O; Visser PJ; Berkhof J; van der Flier WM;
Lancet Neurol; 2019 Nov; 18(11):1034-1044. PubMed ID: 31526625
[TBL] [Abstract][Full Text] [Related]
37. Comparisons of neurodegeneration over time between healthy ageing and Alzheimer's disease cohorts via Bayesian inference.
Cespedes MI; Fripp J; McGree JM; Drovandi CC; Mengersen K; Doecke JD
BMJ Open; 2017 Feb; 7(2):e012174. PubMed ID: 28174220
[TBL] [Abstract][Full Text] [Related]
38. Application of Digital Cognitive Biomarkers for Alzheimer's Disease: Identifying Cognitive Process Changes and Impending Cognitive Decline.
Bock JR; Hara J; Fortier D; Lee MD; Petersen RC; Shankle WR
J Prev Alzheimers Dis; 2021; 8(2):123-126. PubMed ID: 33569557
[TBL] [Abstract][Full Text] [Related]
39. The Association Between Biomarkers and Neuropsychiatric Symptoms Across the Alzheimer's Disease Spectrum.
Banning LCP; Ramakers IHGB; Köhler S; Bron EE; Verhey FRJ; de Deyn PP; Claassen JAHR; Koek HL; Middelkoop HAM; van der Flier WM; van der Lugt A; Aalten P; ;
Am J Geriatr Psychiatry; 2020 Jul; 28(7):735-744. PubMed ID: 32088096
[TBL] [Abstract][Full Text] [Related]
40. Neuroimaging biomarkers of glial activation for predicting the annual cognitive function decline in patients with Alzheimer's disease.
Yasuno F; Kimura Y; Ogata A; Ikenuma H; Abe J; Minami H; Nihashi T; Yokoi K; Hattori S; Shimoda N; Watanabe A; Kasuga K; Ikeuchi T; Takeda A; Sakurai T; Ito K; Kato T
Brain Behav Immun; 2023 Nov; 114():214-220. PubMed ID: 37648003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
